Yamamoto-Sugitani et al. also showed that high level of galectin-3 expression in chronic myelogenous leukemia prompted drug resistance through activation of Akt and Erk [39]. The gene discussed is LGALS3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.